Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Pediatric Acute Leukemia (PedAL) screening trial: developing new therapies for relapsed leukemias

Michele Redell, MD, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, introduces the Pediatric Acute Leukemia (PedAL) initiative and associated screening protocol APAL2020SC (NCT04726241), which are taking place in parallel across North America, Australia, New Zealand, and Europe. The main aims of the trial are to use clinical and biological characteristics to screen for eligibility for therapeutic sub-trials and to maintain a longitudinal data registry and biobank for relapsed leukemias. The biological and clinical data collected at relapse (the point of entry into the trial) is provided to treating physicians to aid them in making the best decisions when treating their patients. As data is collected on the therapeutic approaches opted for by physicians, this provides important insights into treatment patterns. Dr Redell hopes that this longitudinal data registry will inform the design of future clinical trials and that the biobank will support innovative translational research to aid in developing new agents. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.